US 12,286,471 B2
Inhibitors of complement factor H
Edward F. Patz, Jr., Durham, NC (US); Michael J. Campa, Durham, NC (US); Elizabeth Gottlin, Durham, NC (US); Barton F. Haynes, Durham, NC (US); Hua-Xin Liao, Durham, NC (US); and M. Anthony Moody, Durham, NC (US)
Assigned to Duke University, Durham, NC (US)
Filed by Duke University, Durham, NC (US)
Filed on Jan. 3, 2024, as Appl. No. 18/403,218.
Application 18/403,218 is a continuation of application No. 17/458,019, filed on Aug. 26, 2021, granted, now 11,897,946.
Application 17/458,019 is a continuation of application No. 16/196,758, filed on Nov. 20, 2018, granted, now 11,136,380, issued on Oct. 5, 2021.
Application 16/196,758 is a continuation of application No. 14/895,963, granted, now 10,183,988, issued on Jan. 22, 2019, previously published as PCT/US2014/041441, filed on Jun. 7, 2014.
Claims priority of provisional application 61/832,434, filed on Jun. 7, 2013.
Claims priority of provisional application 61/926,539, filed on Jan. 13, 2014.
Prior Publication US 2024/0352101 A1, Oct. 24, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/46 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 14/72 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 14/72 (2013.01); G01N 33/6872 (2013.01); G01N 33/6878 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 16/2863 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/4716 (2013.01)] 6 Claims
 
1. A pharmaceutical composition comprising an isolated antibody or antibody fragment thereof which immunospecifically binds to Complement Factor H (CFH) protein, wherein the isolated antibody or antibody fragment thereof binds to an epitope of PIDNGDIT (SEQ ID NO: 3) within short consensus repeat (SCR) 19 of CFH protein, wherein the antibody comprises:
(a) a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 73 and a variable light domain region comprising the amino acid sequence of SEQ ID NO: 84;
(b) a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 74 and a variable light domain region comprising the amino acid sequence of SEQ ID NO: 83;
(c) a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 75 and a variable light domain region comprising the amino acid sequence of SEQ ID NO: 85;
(d) a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 78 and a variable light domain region comprising the amino acid sequence of SEQ ID NO: 88;
(e) a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 79 and a variable light domain region comprising the amino acid sequence of SEQ ID NO: 89;
(f) a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 76 and a variable light domain region comprising the amino acid sequence of SEQ ID NO: 86; or
(g) a variable heavy domain comprising the amino acid sequence of SEQ ID NO: 77 and a variable light domain region comprising the amino acid sequence of SEQ ID NO: 87.